Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-07-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.12240 |
| _version_ | 1811308600442748928 |
|---|---|
| author | Takako Mukai Miki Egawa Tamaki Takeuchi Hitoshi Yamashita Tatsuya Kusudo |
| author_facet | Takako Mukai Miki Egawa Tamaki Takeuchi Hitoshi Yamashita Tatsuya Kusudo |
| author_sort | Takako Mukai |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays important roles in intracellular lipid metabolism in the liver. We investigated the effect of repression of FABP1 expression on NAFLD, using adenovirus‐mediated silencing of FABP1. FABP1 knockdown in the liver decreased the liver weight and hepatic triglyceride (TG) accumulation. The expression of inflammatory and oxidative stress markers in the liver was also reduced. The level of thiobarbituric acid‐reactive substances, a marker of lipid peroxidation, in the liver of FABP1 knockdown mice was significantly decreased. These results suggest that FABP1 reduction in the liver is an effective approach against NAFLD. |
| first_indexed | 2024-04-13T09:26:06Z |
| format | Article |
| id | doaj.art-fb22317f70ef4eb0a974f4ed3b7eb923 |
| institution | Directory Open Access Journal |
| issn | 2211-5463 |
| language | English |
| last_indexed | 2024-04-13T09:26:06Z |
| publishDate | 2017-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | FEBS Open Bio |
| spelling | doaj.art-fb22317f70ef4eb0a974f4ed3b7eb9232022-12-22T02:52:26ZengWileyFEBS Open Bio2211-54632017-07-01771009101610.1002/2211-5463.12240Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver diseaseTakako Mukai0Miki Egawa1Tamaki Takeuchi2Hitoshi Yamashita3Tatsuya Kusudo4Faculty of Human Sciences Tezukayama Gakuin University Sakai JapanDepartment of Biomedical Sciences College of Life and Health Sciences Chubu University Kasugai JapanDepartment of Biomedical Sciences College of Life and Health Sciences Chubu University Kasugai JapanDepartment of Biomedical Sciences College of Life and Health Sciences Chubu University Kasugai JapanFaculty of Human Sciences Tezukayama Gakuin University Sakai JapanNonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays important roles in intracellular lipid metabolism in the liver. We investigated the effect of repression of FABP1 expression on NAFLD, using adenovirus‐mediated silencing of FABP1. FABP1 knockdown in the liver decreased the liver weight and hepatic triglyceride (TG) accumulation. The expression of inflammatory and oxidative stress markers in the liver was also reduced. The level of thiobarbituric acid‐reactive substances, a marker of lipid peroxidation, in the liver of FABP1 knockdown mice was significantly decreased. These results suggest that FABP1 reduction in the liver is an effective approach against NAFLD.https://doi.org/10.1002/2211-5463.12240FABP1NAFLD |
| spellingShingle | Takako Mukai Miki Egawa Tamaki Takeuchi Hitoshi Yamashita Tatsuya Kusudo Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease FEBS Open Bio FABP1 NAFLD |
| title | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| title_full | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| title_fullStr | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| title_full_unstemmed | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| title_short | Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease |
| title_sort | silencing of fabp1 ameliorates hepatic steatosis inflammation and oxidative stress in mice with nonalcoholic fatty liver disease |
| topic | FABP1 NAFLD |
| url | https://doi.org/10.1002/2211-5463.12240 |
| work_keys_str_mv | AT takakomukai silencingoffabp1ameliorateshepaticsteatosisinflammationandoxidativestressinmicewithnonalcoholicfattyliverdisease AT mikiegawa silencingoffabp1ameliorateshepaticsteatosisinflammationandoxidativestressinmicewithnonalcoholicfattyliverdisease AT tamakitakeuchi silencingoffabp1ameliorateshepaticsteatosisinflammationandoxidativestressinmicewithnonalcoholicfattyliverdisease AT hitoshiyamashita silencingoffabp1ameliorateshepaticsteatosisinflammationandoxidativestressinmicewithnonalcoholicfattyliverdisease AT tatsuyakusudo silencingoffabp1ameliorateshepaticsteatosisinflammationandoxidativestressinmicewithnonalcoholicfattyliverdisease |